BDTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Black Diamond Therapeutics Inc (BDTX) is not a good buy for a beginner investor with a long-term focus at this time. The stock shows weak technical indicators, no strong positive trading signals, and poor financial performance. Additionally, there are no recent news catalysts or significant insider or hedge fund activity to support a bullish case.
The technical indicators are weak: the MACD is slightly positive but contracting, the RSI is neutral at 41.98, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 2.081 and resistance at 2.264, indicating a bearish trend.
Analyst Wedbush raised the price target to $14 and maintains an Outperform rating, citing potential for silevertinib clinical development and upcoming data readouts. Gross margin remains at 100%.
The stock has a 60% chance of declining in the next week (-3.51%) and next month (-2.79%). Financial performance is poor, with net income and EPS declining YoY. No significant hedge fund or insider trading activity. No recent news or congress trading data to act as a catalyst.
In Q4 2025, revenue remained at $0, net income dropped by -5.44% YoY to -$15.12M, and EPS fell by -7.14% YoY to -0.26. Gross margin stayed at 100%, but there is no revenue growth.
Analyst sentiment is mixed but slightly positive. Wedbush raised the price target from $13 to $14 with an Outperform rating, while Piper Sandler lowered the price target from $9 to $8 but maintains an Overweight rating.
